DCG-IV

DCG-IV
(IUPAC) ime
	(1R,2R)-3-[(1S)-1-amino-2-hidroksi-2-oksoetil]ciklopropan-1,2-dikarboksilna kiselina
Klinički podaci
Identifikatori
CAS broj	147782-19-2
ATC kod	nije dodeljen
PubChem	5310979
Hemijski podaci
Formula	C7H9NO6
Mol. masa	203,149 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C7H9NO6/c8-4(7(13)14)1-2(5(9)10)3(1)6(11)12/h1-4H,8H2,(H,9,10)(H,11,12)(H,13,14)/t2-,3-,4+/m1/s1 ; Key: MATPZHBYOVDBLI-JJYYJPOSSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

DCG-IV je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist za grupu II metabotropnih glutamatnih receptora (mGluR₂_/₃).^[3] On ima potentne neuroprotektivne i antikonvulsantne efekte u životinjskim studijama.^[4]^[5]^[6]^[7] On isto tako pokazuje antiparkinsonove efekte,^[8]^[9] mada je poznato da usporava formiranje memorija.^[10]^[11]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (August 1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology 109 (4): 1169–77. PMC 2175774. PMID 8401927.
↑ Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology 256 (1): 109–12. DOI:10.1016/0014-2999(94)90624-6. PMID 7517889.
↑ Yoshioka H, Sugita M, Kinouchi H (September 2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters 461 (3): 266–70. DOI:10.1016/j.neulet.2009.06.056. PMID 19549561.
↑ Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research 805 (1-2): 138–43. DOI:10.1016/S0006-8993(98)00698-2. PMID 9733953.
↑ Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience 13 (10): 1023–7. DOI:10.1016/j.jocn.2005.11.042. PMID 17113985.
↑ Dawson L, Chadha A, Megalou M, Duty S (February 2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology 129 (3): 541–6. DOI:10.1038/sj.bjp.0703105. PMC 1571875. PMID 10711353.
↑ Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience 113 (4): 857–69. DOI:10.1016/S0306-4522(02)00232-4. PMID 12182892.
↑ Huang LQ, Rowan MJ, Anwyl R (February 1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport 8 (3): 687–93. DOI:10.1097/00001756-199702100-00022. PMID 9106748.
↑ Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior 80 (5): 747–58. DOI:10.1016/j.physbeh.2003.12.010. PMID 14984810.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid8401927-3] Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (August 1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology 109 (4): 1169–77. PMC 2175774. PMID 8401927.

[pmid7517889-4] Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology 256 (1): 109–12. DOI:10.1016/0014-2999(94)90624-6. PMID 7517889.

[pmid19549561-5] Yoshioka H, Sugita M, Kinouchi H (September 2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters 461 (3): 266–70. DOI:10.1016/j.neulet.2009.06.056. PMID 19549561.

[pmid9733953-6] Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research 805 (1-2): 138–43. DOI:10.1016/S0006-8993(98)00698-2. PMID 9733953.

[pmid17113985-7] Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience 13 (10): 1023–7. DOI:10.1016/j.jocn.2005.11.042. PMID 17113985.

[pmid10711353-8] Dawson L, Chadha A, Megalou M, Duty S (February 2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology 129 (3): 541–6. DOI:10.1038/sj.bjp.0703105. PMC 1571875. PMID 10711353.

[pmid12182892-9] Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience 113 (4): 857–69. DOI:10.1016/S0306-4522(02)00232-4. PMID 12182892.

[pmid9106748-10] Huang LQ, Rowan MJ, Anwyl R (February 1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport 8 (3): 687–93. DOI:10.1097/00001756-199702100-00022. PMID 9106748.

[pmid14984810-11] Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior 80 (5): 747–58. DOI:10.1016/j.physbeh.2003.12.010. PMID 14984810.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]